Moteur de recherche d’entreprises européennes
Financement de l’UE (19,9 M €) : Mise en place d’une prédiction personnalisée du risque et de la prévention de la mort subite d’origine cardiaque après un infarctus du myocarde Hor 01/01/2020 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Mise en place d’une prédiction personnalisée du risque et de la prévention de la mort subite d’origine cardiaque après un infarctus du myocarde
Sudden cardiac death (SCD) is a major public health problem accounting for ~20% of all deaths in Europe with an estimated yearly incidence of ~350-700,000, often in patients with previous myocardial infarction (MI). In SCD, the heart suddenly and unexpectedly stops beating. If untreated, the patient dies within minutes, but SCD can be successfully prevented by an implantable cardioverter-defibrillator (ICD). The ICD is highly effective, but is associated with potentially severe complications and high healthcare costs. Based on historical evidence, guidelines recommend prophylactic ICD implantation in post-MI patients with left ventricular ejection fraction (LVEF)≤35% to prevent SCD. However, only a minority of these patients will ever need the device. In addition, in absolute numbers the majority of SCD cases occurs in patients with LVEF>35% who are currently not considered for prophylactic ICD. Due to the inherent risks and considerable health care expenditures, a personalised treatment approach for ICD implantation is urgently required. Using state-of-the-art methods and large clinical datasets from established international cohorts and registries across different European geographies, PROFID will develop a clinical decision support tool (risk score) to predict the individual SCD risk and identify those post-MI patients that will optimally benefit from an ICD. Two parallel randomised clinical trials will validate implementation of the risk score to determine ICD implantation, while health economic analyses will assess its economic impact on health care systems. A software tool for clinical use of the risk score will be implemented, and a pilot run in 3 European regions with participation of insurance companies and authorities. The unique composition of the consortium with key opinion leaders, patient organisations, large hospital chains, payers, policy makers and state authorities across Europe, will ensure implementation into routine clinical practice.
| Aarhus Universitet | 50 000 € |
| Aarhus Universitetshospital | 135 000 € |
| Aston University | 150 000 € |
| Barmer Ersatzkasse | 172 709 € |
| Catalyze B.V. | 16 800,00 € |
| Charite - Universitaetsmedizin Berlin | 6 029 393 € |
| Clinique Pasteur SA | 167 563 € |
| CRI - THE Clinical Research Institute GmbH | 6 767 383 € |
| Deutsche Herzstiftung | 198 750 € |
| Fakultni Nemocnice Olomouc | 185 000 € |
| Helios Health Institute GmbH | 973 388 € |
| Idcq Hospitales y Sanidad SL | 221 629 € |
| Instituto Investigacion Sanitaria Fundacion Jimenez Diaz | 83 500 € |
| Istituto Auxologico Italiano | 151 875 € |
| Leipzig Heart Science Gemeinnutzigegesellschaft mbH | 0,00 € |
| Region Stockholm | 185 000 € |
| SE de Cardiologie | 248 125 € |
| Semmelweis Egyetem | 185 000 € |
| Slaski Uniwersytet Medyczny w Katowicach | 245 625 € |
| Stichting Amsterdam UMC | 1 104 375 € |
| Stichting Netherlands Heart Institute | 0,00 € |
| THE Health Corporation - Rambam | 185 000 € |
| The University of Manchester | 928 524 € |
| Universitat Bayreuth | 437 125 € |
| University of Leeds | 295 000 € |
| University of York | 767 806 € |
https://cordis.europa.eu/project/id/847999
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.